Ibritumomab Biosimilar Monoclonal Antibody (CD20) for Research

Cat No.: GMP-Bios-INN-1228

Anti-MS4A1/CD20 therapeutic antibody (Pre-made Ibritumomab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Ibritumomab (development code IDEC-129, brand name Zevalin) is a murine anti-CD20 monoclonal antibody conjugated to the radioisotope yttrium-90. It is used for the treatment of non-Hodgkin lymphoma. It was the first radioimmunotherapy approved by the FDA.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1228-1mg 1mg 3090
GMP-Bios-INN-1228-10mg 10mg
GMP-Bios-INN-1228-100mg 100mg
GMP-Bios-INN-1228-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Ibritumomab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-CD20/MS4A1/B-lymphocyte antigen CD20/B-lymphocyte surface antigen B1 therapeutic antibody
INN Name Ibritumomab
Target MS4A1/CD20
Format Whole mAb
Derivation Mus musculus
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Kappa
Highest_Clin_Trial (Jan '20) Approved
Est. Status NFD
100% SI Structure 3bky:HL
99% SI Structure None
95-98% SI Structure None
Year Proposed 1999
Year Recommended 2000
Companies Biogen;Schering;Spectrum Pharmaceuticals
Conditions Approved Non-Hodgkin's lymphoma
Conditions Active na
Conditions Discontinued Diffuse large B cell lymphoma;Mantle-cell lymphoma;Marginal zone B-cell lymphoma;Multiple myeloma
Production na
Development Tech na